Relmada Therapeutics company info

What does Relmada Therapeutics do?
Relmada Therapeutics (NASDAQ:RLMD) is a clinical-stage biotech company focused on developing novel therapies for the treatment of central nervous system (CNS) diseases, particularly those related to depression and other psychiatric disorders. Their portfolio includes multiple innovative projects aiming to address the unmet medical needs in mental health and pain management. One of their flagship products, REL-1017, is an NMDA receptor antagonist currently in advanced clinical trials for major depressive disorder, showcasing their commitment to pioneering treatments that can improve patient outcomes. With a clear objective to revolutionize the landscape of psychiatric and neurological care, Relmada Therapeutics is dedicated to advancing its research and development efforts to bring new, effective therapeutic options to market.
Relmada Therapeutics company media
Company Snapshot

Is Relmada Therapeutics a public or private company?


How many people does Relmada Therapeutics employ?


What sector is Relmada Therapeutics in?

pie chart
Health Care

Where is the head office for Relmada Therapeutics?

location pin
Head Office
Coral Gables, United States

What year was Relmada Therapeutics founded?

founded flag
Year Founded
What does Relmada Therapeutics specialise in?
/Pharmaceutical Development /Depression Treatment /Chronic Pain Relief /Central Nervous System /Clinical Trials /Drug Innovation

What are the products and/or services of Relmada Therapeutics?

Overview of Relmada Therapeutics offerings
Relmioram, a novel NMDA receptor antagonist for major depressive disorder, in Phase 3 clinical trials.
Development of therapies targeting central nervous system (CNS) diseases, including chronic pain.
Exploration of novel formulations and delivery methods for enhanced drug efficacy and patient compliance.
Investigations into potential treatments for neuropathic pain.

Who is in the executive team of Relmada Therapeutics?

Relmada Therapeutics leadership team
  • Dr. Sergio  Traversa M.B.A., Pharm.D.
    Dr. Sergio Traversa M.B.A., Pharm.D.
    CEO & Director
  • Mr. Maged S. Shenouda M.B.A., R.Ph.
    Mr. Maged S. Shenouda M.B.A., R.Ph.
    Chief Financial Officer
  • Mr. Charles S. Ence CPA, M.B.A.
    Mr. Charles S. Ence CPA, M.B.A.
    Chief Accounting & Compliance Officer
  • Dr. Paolo  Manfredi M.D., Ph.D.
    Dr. Paolo Manfredi M.D., Ph.D.
    Chief Scientific Officer
  • Ms. Gina  DiGuglielmo
    Ms. Gina DiGuglielmo
    VP & Head of Clinical Operations
  • Dr. Marco  Pappagallo M.D.
    Dr. Marco Pappagallo M.D.
    Chief Clinical Officer
  • Mr. John  Hixon
    Mr. John Hixon
    Head of Commercial
  • Dr. Andrew  Cutler
    Dr. Andrew Cutler
    Senior Clinical Development Advisor